Search results
Results from the WOW.Com Content Network
Cholesterol synthesis appears to occur mostly at night, [140] so statins with short half-lives are usually taken at night to maximize their effect. Studies have shown greater LDL and total cholesterol reductions in the short-acting simvastatin taken at night rather than the morning, [141] [142] but have shown no difference in the long-acting ...
Statin-associated autoimmune myopathy (SAAM), also known as anti-HMGCR myopathy, is a very rare form of muscle damage caused by the immune system in people who take statin medications. [1] However, there are cases of SAAM in patients who have not taken statin medication, and this can be explained by the exposure to natural sources of statin ...
The activity of each statin is dependent on the binding affinity of the compound for the substrate site and the length of time it binds to the site. [5] Type 2 statins have unique fluorophenyl group that causes additional polar interaction between the enzyme and the statins, which results in a tighter binding to the enzyme.
Why statins are prescribed Women develop cardiovascular disease less often than men, according to a study published in 2023. However, they have a higher rate of death from cardiovascular disease.
Current guidelines suggest that most adults need at least seven hours of sleep a night, but Ercoli points out that everyone’s sleep requirements are slightly different. “I try to get around ...
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor ...
“In addition, [poor] sleep duration and quality are both considered risk factors for type 2 diabetes.” , If you’re not getting seven hours per night, start by going to bed 15 minutes earlier ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.